

September 24, 2008

APA DSM-V Work Group Member

Name, Degree: Wolfgang Gaebel, Professor Dr. med., M.D.

Role(s) in Work Group: Member, Psychotic Disorders Work Group

Institutional Affiliation(s): Heinrich-Heine-University Duesseldorf, Dept of Psychiatry and Psychotherapy, Director; Rhineland State Clinics, Medical Director

City, State: Düsseldorf, Germany

Biographical Sketch:

Wolfgang Gaebel, Prof. Dr. med., MD

Member DSM-V Work Group on Psychotic disorders for the development of the Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM-V)

Professor Gaebel qualified in medicine in 1972 at the Free University of Berlin (FUB), Germany, then took up postgraduate training in Neurology at Rudolf-Virchow-Hospital in Berlin and Psychiatry at the Department of Psychiatry at the FUB. After specializing in Psychiatry, Psychotherapy and Neurology he continued working as Research Assistant, then Senior Psychiatrist at the Department of Psychiatry at the FUB, at the same time becoming appointed as State Physician for Mentally Handicapped Persons at the Senator for Health and Social Affairs in Berlin. In 1989 he obtained a grant of the German Research Foundation for a Research Stay at the Department of Psychology at the University of Lethbridge, Alberta, Canada. In 1992 he took up his present position.

During his career, Professor Gaebel has held positions as President of the German Society of Psychiatry, Psychotherapy and Nervous Diseases (DGPPN, 1995/6), and President of the German Society of Biological Psychiatry (DGBP, 1999-02). He was Chair of the Organizing Committee of the 11th WPA World Congress of Psychiatry, Hamburg, 1999. He is Vice President of the Association of the Scientific Medical Societies in Germany (AWMF), member of the Deutsche Akademie der Naturforscher (German Academy of Sciences) LEOPOLDINA, member of several National Ethical Committees, chairman of the Section on Schizophrenia as well as co-chairman of the Section on Quality Assurance and honorary member of the World Psychiatric Association (WPA), and chairman of the Task Force on Nosology and Psychopathology of the World Federation of Societies of Biological Psychiatry (WFSBP).

Prof. Gaebel was again elected as President of the German Society of Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) for the period 2007/8. He was elected as a Board Member of the European Psychiatric Association (EPA) with effect of 01 January 2009. Since 2006 he is chairman of the German Network on Mental Health.

His research focus includes clinical, pharmacological, and neurophysiological aspects of schizophrenia; experimental psychopathology; treatment guidelines and quality management, and research on stigma and discrimination. He has (co-)initiated a number of research networks and is speaker of the Addiction Research Network North-Rhine Westphalia and the German Competence Network on Schizophrenia (GCNS), both funded by the German Federal Ministry of Education and Research. In 2007 on behalf of the GCNS Professor Gaebel initiated the 1st European Conference on Schizophrenia Research, held in Duesseldorf and co-sponsored by EPA and WPA.

His current scientific interests include the development of diagnosis and classification towards ICD-11 and DSM-V; he is a member of the coordination group of the Global Scientific Partnership Network (GSPN) appointed by WHO, chairing the German language

expert panel contributing to the development of ICD-11.

Professor Gaebel has published about 500 scientific articles and is editor or author of about 30 books/supplements on a range of topics.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role (honorary appointments)
German Society of Psychiatry, Psychotherapy and Nervous Diseases (DGPPN)	2007 – 2008	President
German Society of Biological Psychiatry (DGBP)	2005 – 2007	Vice president
German Network on Mental Health	2006 –	Chair
World Psychiatric Association (WPA): Section on schizophrenia	2002 –	Chair
World Psychiatric Association (WPA): Section on quality assurance	1996 –	Co-Chair
Global Scientific Partnership Network (WHO): German language expert panel	2007 – 2008	Chair
World Federation of Societies of Biological Psychiatry (WFSBP): Task Force on Nosology and Psychopathology	2005 – 2008	Chair
German Academy of Sciences (Leopoldina)	2001 –	Member
European Psychiatric Association (EPA)	2009	Board Member

The two tables below represent Prof. Dr. Wolfgang Gaebel's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Prof. Dr. Wolfgang Gaebel has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, his aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial Organizations	Year(s)	Key #(s)
Astra Zeneca GmbH, Wedel	2005 – 2007	3, 4
Bristol-Myers Squibb GmbH, München	2005 – 2007 2006	3 4
Eli Lilly Foundation	2005	3
Janssen-Cilag GmbH, Neuss	2005 – 2007	1, 3, 4, 10 (scientific symposia)
Lilly Deutschland GmbH, Bad Homburg	2005 – 2007	1, 4, 10 (scientific symposia)
Lundbeck GmbH & Co., Hamburg	2005 – 2007 2006	4 1
Lundbeck Foundation	2005 – 2007	1
Novartis, Nürnberg	2005, 2007	1, 4, 10 (scientific symposia)
Wyeth Pharma GmbH, Münster	2005 – 2007	1, 4, 10 (scientific symposia)

Non-Commercial Organizations	Year(s)	Key#(s)
German Federal Ministry of Research and Education (BMBF) <ul style="list-style-type: none"> • Competence Net on Schizophrenia • Competence Net on Depression • Addiction Research Network • BrainNet 	2005 – 2007 2005 – 2007 2005 – 2007 2005	Non commercial grant research 10 10 10 10
BMBF <ul style="list-style-type: none"> • Competence Net on Dementia (Research Cooperation) • Competence Net on Schizophrenia (Research Cooperation) 	2005 – 2007 2005	Non commercial grant research 10 10
German Federal Ministry of Health (BMG)	2005 – 2006	Non commercial grant research 10
German Research Foundation (DFG) Research Cooperation	2006 – 2007	Non commercial grant research 10
Robert-Koch-Institute	2005 – 2006	Non commercial grant research 10
Sick Fund (TKK)	2005 – 2006	Non commercial grant research 10
Telematic Platform (TMF)	2006 – 2007	Non commercial grant research 10

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial Organizations	Year(s)	Key #(s)
Astra Zeneca GmbH, Wedel	2008	4, 10 (scientific symposia)
Janssen-Cilag GmbH, Neuss	2008	1, 3, 4, 10 (scientific symposia)
Lilly Deutschland GmbH, Bad Homburg	2008	1, 3, 4, 10 (scientific symposia)
Lundbeck Institute, Denmark	2008	4
Non-Commercial Organizations	Year(s)	Key#(s)
German Federal Ministry of Research and Education (BMBF) <ul style="list-style-type: none"> • Competence Net on Schizophrenia • Competence Net on Depression 	2008 – 2009 2008	Non commercial grant research 10 10
German Research Foundation (DFG) Research Cooperation	2008	Non commercial grant research 10